ATE399162T1 - Flavon derivate als inhibitoren von cyclin- abhängigen kinasen - Google Patents

Flavon derivate als inhibitoren von cyclin- abhängigen kinasen

Info

Publication number
ATE399162T1
ATE399162T1 AT03753911T AT03753911T ATE399162T1 AT E399162 T1 ATE399162 T1 AT E399162T1 AT 03753911 T AT03753911 T AT 03753911T AT 03753911 T AT03753911 T AT 03753911T AT E399162 T1 ATE399162 T1 AT E399162T1
Authority
AT
Austria
Prior art keywords
cyclin
inhibitors
dependent kinases
flavone derivatives
flavone
Prior art date
Application number
AT03753911T
Other languages
English (en)
Inventor
Bansi Lal
Kalpana Joshi
Sanjeev Kulkarni
Malcolm Mascarenhas
Shrikant Kamble
Maggie Rathos
Rajendrakumar Joshi
Original Assignee
Nicholas Piramal India Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicholas Piramal India Ltd filed Critical Nicholas Piramal India Ltd
Application granted granted Critical
Publication of ATE399162T1 publication Critical patent/ATE399162T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT03753911T 2002-07-08 2003-07-07 Flavon derivate als inhibitoren von cyclin- abhängigen kinasen ATE399162T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN616MU2002 2002-07-08

Publications (1)

Publication Number Publication Date
ATE399162T1 true ATE399162T1 (de) 2008-07-15

Family

ID=30012269

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03753911T ATE399162T1 (de) 2002-07-08 2003-07-07 Flavon derivate als inhibitoren von cyclin- abhängigen kinasen

Country Status (20)

Country Link
EP (1) EP1556375B1 (de)
JP (1) JP4860148B2 (de)
KR (1) KR100991920B1 (de)
CN (1) CN1668613B (de)
AR (1) AR041184A1 (de)
AT (1) ATE399162T1 (de)
AU (1) AU2003272070B2 (de)
BR (1) BR0312633A (de)
CA (1) CA2492130C (de)
DE (1) DE60321808D1 (de)
DK (1) DK1556375T3 (de)
ES (1) ES2309338T3 (de)
IL (1) IL166153A (de)
MX (1) MXPA05000388A (de)
NZ (1) NZ537518A (de)
PT (1) PT1556375E (de)
RU (1) RU2334746C2 (de)
TW (1) TWI331034B (de)
WO (1) WO2004004632A2 (de)
ZA (1) ZA200500138B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7915301B2 (en) 2002-07-08 2011-03-29 Piramal Life Science Limited Inhibitors of cyclin dependent kinases and their use
JP5498782B2 (ja) * 2006-06-21 2014-05-21 ピラマル エンタープライジーズ リミテッド 増殖性疾患治療用のエナンチオマー的に純粋なフラボン誘導体の調製方法
RU2404965C2 (ru) * 2006-07-07 2010-11-27 Пирамал Лайф Сайнсиз Лимитед Способ энантиоселективного синтеза промежуточных соединений, используемых при получении пирролидинов, замещенных флавонами
ATE517892T1 (de) 2006-07-07 2011-08-15 Piramal Life Sciences Ltd Enantioselektive synthese pyrrolidinsubstituierter flavone
RU2438664C2 (ru) * 2007-05-15 2012-01-10 Пирамал Лайф Сайнсиз Лимитед Синергическая фармацевтическая комбинация для лечения рака
EP2154971B1 (de) * 2007-05-15 2011-12-28 Piramal Life Sciences Limited Synergistische pharmazeutische kombination für die behandlung von krebs
CN101333205A (zh) * 2008-07-10 2008-12-31 大连理工大学 周期素依赖蛋白激酶抑制剂黄芩素哌嗪衍生物及其制法
TWI461194B (zh) 2009-05-05 2014-11-21 Piramal Entpr Ltd 吡咯啶取代黃酮作為輻射致敏劑
EP2429292B1 (de) * 2009-05-08 2019-04-03 Georgia State University Research Foundation Verbindungen und zusammensetzungen mit cdk-hemmern und deren verwendung zur behandlung von krebs
US7928067B2 (en) 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
WO2011104584A1 (en) * 2010-02-26 2011-09-01 Piramal Life Sciences Limited Pyrrolidine substituted flavones for the treatment of inflammatory disorders
US8815937B2 (en) 2010-11-18 2014-08-26 Ischemix Llc Lipoyl compounds and their use for treating ischemic injury
WO2012069972A1 (en) 2010-11-19 2012-05-31 Piramal Life Sciences Limited A pharmaceutical combination for the treatment of breast cancer
AU2011330733A1 (en) * 2010-11-19 2013-06-06 Piramal Enterprises Limited Pharmaceutical combination of paclitaxel and a CDK inhibitor
TW201242597A (en) 2011-03-14 2012-11-01 Piramal Life Sciences Ltd A synergistic pharmaceutical combination for the treatment of pancreatic cancer
UY34013A (es) * 2011-04-13 2012-11-30 Astrazeneca Ab ?compuestos de cromenona con actividad anti-tumoral?.
TW201300105A (zh) 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
AU2012274990A1 (en) 2011-06-24 2014-02-06 Piramal Enterprises Limited Compounds for the treatment of cancers associated with human papillomavirus
EP2802323B1 (de) 2012-01-13 2016-08-10 Piramal Enterprises Limited Pyrrolidine-substituierte flavonderivate zur prävention oder behandlung oraler mucositis
WO2014049515A1 (en) * 2012-09-25 2014-04-03 Piramal Enterprises Limited Pyrrolidine substituted flavones for treatment of renal cystic diseases
CN111053768B (zh) 2013-07-12 2023-12-12 皮拉马尔企业有限公司 用于治疗黑素瘤的药物组合
US10555931B2 (en) 2014-05-28 2020-02-11 Piramal Enterprises Limited Pharmaceutical combination for the treatment of cancer
KR20180019200A (ko) * 2015-06-23 2018-02-23 코베스트로 도이칠란트 아게 치환된 트리아진 및 그의 제조 방법
CA3103604C (en) 2016-03-28 2023-09-26 Presage Biosciences, Inc. Pharmaceutical combinations for the treatment of cancer
US10849903B2 (en) 2016-10-20 2020-12-01 Pfizer Inc. Anti-proliferative agents for treating PAH
AU2018258158A1 (en) 2017-04-25 2019-11-21 Ischemix Llc Compositions and methods for treating traumatic brain injury
CN107573270B (zh) * 2017-09-29 2019-11-29 河南师范大学 一种α-甲酰基吡咯烷类化合物的合成方法
WO2020079106A1 (en) 2018-10-19 2020-04-23 F. Hoffmann-La Roche Ag Chromen-4-one derivatives for the treatment and prophylaxis of hepatitis b virus disease
CN110028475B (zh) * 2019-05-13 2022-07-01 中国药科大学 基于苯并吡喃结构的新型cdk9抑制剂、其制备方法及应用
CR20220236A (es) 2019-11-28 2022-10-03 Bayer Pharma AG Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune
AR121719A1 (es) 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
KR20240004865A (ko) 2021-05-03 2024-01-11 페트라 파마 코포레이션 질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제
EP4347040A1 (de) 2021-05-27 2024-04-10 Petra Pharma Corporation Allosterische chromenoninhibitoren von phosphoinositid-3-kinase (pi3k) zur behandlung von krebs
CN113549044B (zh) * 2021-07-23 2024-01-23 中国药科大学 8-氮杂环取代色酮类衍生物及其制备方法与制药用途
TW202329930A (zh) 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3836676A1 (de) * 1988-10-28 1990-05-03 Hoechst Ag Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
HUT72741A (en) * 1992-12-19 1996-05-28 Alkaloida Vegyeszeti Gyar Method for producing benzopyrane derivatives and pharmaceutical compositions containing them
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5849733A (en) * 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
EP1280789A1 (de) * 2000-05-03 2003-02-05 LG Life Sciences Ltd. Cdk-inhibitoren mit 3-hydroxychromen-4-on-struktur

Also Published As

Publication number Publication date
CN1668613A (zh) 2005-09-14
ZA200500138B (en) 2006-02-22
IL166153A0 (en) 2006-01-15
JP2006502109A (ja) 2006-01-19
IL166153A (en) 2009-11-18
JP4860148B2 (ja) 2012-01-25
PT1556375E (pt) 2008-10-03
CA2492130A1 (en) 2004-01-15
RU2334746C2 (ru) 2008-09-27
DE60321808D1 (de) 2008-08-07
TW200406202A (en) 2004-05-01
WO2004004632A2 (en) 2004-01-15
WO2004004632A3 (en) 2004-09-16
MXPA05000388A (es) 2005-09-30
NZ537518A (en) 2008-02-29
ES2309338T3 (es) 2008-12-16
TWI331034B (en) 2010-10-01
EP1556375B1 (de) 2008-06-25
RU2005102939A (ru) 2005-09-10
EP1556375A2 (de) 2005-07-27
BR0312633A (pt) 2005-07-19
CN1668613B (zh) 2012-07-04
KR100991920B1 (ko) 2010-11-04
AR041184A1 (es) 2005-05-04
DK1556375T3 (da) 2008-11-03
CA2492130C (en) 2011-09-06
AU2003272070A1 (en) 2004-01-23
AU2003272070B2 (en) 2009-02-26
KR20050017110A (ko) 2005-02-21
WO2004004632A8 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
ATE399162T1 (de) Flavon derivate als inhibitoren von cyclin- abhängigen kinasen
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
NO20045220L (no) Heterocykliske inhibitorer for kinaser
ATE370137T1 (de) 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE416171T1 (de) 2-hydroxy-3-heteroarylindole derivate als gsk3 inhibitoren
NO20043158L (no) Substituerte kinazolinderivater som inhibitorer av aurorakinaser
DE60309848D1 (de) Purinderivate als kinaseinhibitoren
DE602005025733D1 (de) Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
NO20050636L (no) Inhibitorer av tyrosinkinaser
IL230659A (en) Calicheamicin derivative-carrier conjugates
ATE413404T1 (de) Triazolopyrimidin derivate als inhibitoren von glycogen synthase kinase-3
DE60315516D1 (de) Pyridazinon-derivate als cdk2-hemmer
DE60305061D1 (de) 2-pyridonderivate als inhibitoren von neutrophiler elastase
DE60316841D1 (de) Triazolderivate als inhibitoren von11-beta-hydroxysteroid-dehydrogenase-1
NO20050072L (no) Nye inhibitorer av kinaser
ATE426599T1 (de) Thiazolylpiperidin derivate als mtp inhibitoren
CY2011016I1 (el) Λακταμουχες ενωσεις και παραγωγα αυτων ως αναστολεις του παραγοντα χα
ATE386730T1 (de) Phenylpiperazinderivate als serotonin wiederaufnahmehemmer
DE60315862D1 (de) Dihydropyridinonderivate als hne-inhibitoren
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
PT1580216E (pt) Derivados de elevado peso molecular de camptotecinas
PT1296981E (pt) Derivados substituidos da pirrolopiridinona uteis como inibidores da fosfodiesterase
ATE393159T1 (de) Heterobicyclische pyrazolderivate als kinaseinhibitoren
ATE382048T1 (de) Pyrazolopyrimdine als hemmstoffe cyclin abhängiger kinasen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1556375

Country of ref document: EP

EEIH Change in the person of patent owner